Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1978 May;5(5):379–399. doi: 10.1111/j.1365-2125.1978.tb01644.x

The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

B N Prichard
PMCID: PMC1429347  PMID: 26370

Abstract

All beta-adrenoceptor blocking drugs that have been described share the common property of being competitive inhibitors. They differ in their associated properties, the presence or absence of cardioselectivity, membrane stabilizing activity, and partial agonist activity. Recently some beta-adrenoceptor blocking drugs have been reported which also possess alpha-adrenoceptor blocking activity. The associated properties have been used as a basis for classifying beta-adrenoceptor blocking drugs (Fitzgerald, 1969, 1972). The presence or absence of cardioselectivity is most useful for dividing beta-adrenoceptor blocking drugs. The non-selective drugs (Division I) can be further divided according to the presence or absence of intrinsic sympathomimetic activity (ISA) and membrane stabilizing activity (Fitzgerald's groups I-IV). Group I possess both membrane activity and ISA, e.g. alprenolol, oxprenolol, group II just membrane action, e.g. propanolol, group III ISA but no membrane action, e.g. pindolol. Fitzgerald placed pindolol in group I but should be placed in group III as it possesses a high degree of beta-adrenoceptor blocking potency in relation to its membrane activity (Prichard, 1974). Finally drugs in group IV have neither ISA nor membrane action, e.g. sotalol, timolol. The cardioselective drugs (Division II) can be similarly sub-divided into groups I-IV according to the presence or absence of ISA or membrane action (Fitzgerald grouped all these together as group V). Lastly there are new beta-adrenergic receptor blocking drugs which in addition have alpha- adrenergic receptor blocking properties (Division III).

Full text

PDF
380

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABLAD B. A study of the mechanism of the hemodynamic effects of hydralazine in man. Acta Pharmacol Toxicol (Copenh) 1963;20(Suppl 1):1–53. [PubMed] [Google Scholar]
  2. APTHORP G. H., CHAMBERLAIN D. A., HAYWARD G. W. THE EFFECTS OF SYMPATHECTOMY ON THE ELECTROCARDIOGRAM AND EFFORT TOLERANCE IN ANGINA PECTORIS. Br Heart J. 1964 Mar;26:218–226. doi: 10.1136/hrt.26.2.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ablad B., Ek L., Johansson B., Waldeck B. Inhibitory effect of propranolol on the vasoconstrictor response to sympathetic nerve stimulation. J Pharm Pharmacol. 1970 Aug;22(8):627–628. doi: 10.1111/j.2042-7158.1970.tb10585.x. [DOI] [PubMed] [Google Scholar]
  4. Adler-Graschinsky E., Langer S. Z. Possible role of a beta-adrenoceptor in the regulation of noradrenaline release by nerve stimulation through a positive feed-back mechanism. Br J Pharmacol. 1975 Jan;53(1):43–50. doi: 10.1111/j.1476-5381.1975.tb07328.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Aenishänslin W., Pestalozzi-Kerpel J., Dubach U. C., Imhof P. R., Turri M. Antihypertensive therapy with adrenergic beta-receptor blockers and vasodilators. Eur J Clin Pharmacol. 1972 Jun;4(3):177–181. doi: 10.1007/BF00561142. [DOI] [PubMed] [Google Scholar]
  6. Ahlmark G., Saetre H., Korsgren M. Letter: Reduction of sudden Deaths after myocardial infarction. Lancet. 1974 Dec 28;2(7896):1563–1563. doi: 10.1016/s0140-6736(74)90299-2. [DOI] [PubMed] [Google Scholar]
  7. Amery A., Billiet L., Boel A., Fagard R., Reybrouck T., Willems J. Mechanism of hypotensive effect during betaadrenergic blockade in hypertensive patients. Am Heart J. 1976 May;91(5):634–642. doi: 10.1016/s0002-8703(76)80149-4. [DOI] [PubMed] [Google Scholar]
  8. Amery A., De Plaen J. F., Fagard R., Linjen P., Reybrouck T. The relationship between beta-blockade, hyporeninaemic and hypotensive effect of two beta-blocking agents. Postgrad Med J. 1976;52 (Suppl 4):102–108. [PubMed] [Google Scholar]
  9. Amsterdam E. A., Gorlin R., Wolfson S. Evaluation of long-term use of propranolol in angina pectoris. JAMA. 1969 Oct 6;210(1):103–106. [PubMed] [Google Scholar]
  10. Anavekar S. N., Louis W. J., Morgan T. O., Doyle A. E., Johnston C. I. The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol. 1975 May-Jun;2(3):203–212. doi: 10.1111/j.1440-1681.1975.tb03026.x. [DOI] [PubMed] [Google Scholar]
  11. Baczko A., Dabrowska B., Wocial B. Ocena działania hipotensyjnego propranololu w leczeniu nadciśnienia tetniczego. Pol Arch Med Wewn. 1967;38(4):397–403. [PubMed] [Google Scholar]
  12. Barrett A. M., Nunn B. Adrenergic neuron blocking properties of (plus or minus)-propranolol and (plus)-propranolol. J Pharm Pharmacol. 1970 Nov;22(11):806–810. doi: 10.1111/j.2042-7158.1970.tb08443.x. [DOI] [PubMed] [Google Scholar]
  13. Beilin L. J., Juel-Jensen B. E. Alpha and beta adrenergic blockade in hypertension. Lancet. 1972 May 6;1(7758):979–982. doi: 10.1016/s0140-6736(72)91154-3. [DOI] [PubMed] [Google Scholar]
  14. Bengtsson C. Comparison between alprenolol and chlorthalidone as antihypertensive agents. Acta Med Scand. 1972 May;191(5):433–439. [PubMed] [Google Scholar]
  15. Bengtsson C., Johnsson G., Regårdh C. G. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther. 1975 Apr;17(4):400–408. doi: 10.1002/cpt1975174400. [DOI] [PubMed] [Google Scholar]
  16. Berglund G. Antihypertensive effect of sotalol and propranolol a double-blind crossover study. Curr Ther Res Clin Exp. 1977 Jan;21(1):21–27. [PubMed] [Google Scholar]
  17. Bergstrand R. H., Vedin J. A., Wilhelmsson C. E., Berglund G. Comparative study of metoprolol and alpha-methyldopa in untreated essential hypertension. Eur J Clin Pharmacol. 1976;10(6):375–379. doi: 10.1007/BF00563072. [DOI] [PubMed] [Google Scholar]
  18. Beumer H. M. Adverse effects of beta-adrenergic receptor blocking drugs on respiratory function. Drugs. 1974;7(1):130–138. doi: 10.2165/00003495-197407010-00009. [DOI] [PubMed] [Google Scholar]
  19. Birkenhäger W. H., Krauss X. H., Schalekamp M. A., Kolsters G., Kroon B. J. Antihypertensive effects of propranolol. Observations on predictability. Folia Med Neerl. 1971;14(2):67–71. [PubMed] [Google Scholar]
  20. Bjerle P., Jacobsson K. A., Agert G. Letter: Paradoxical effect of pindolol. Br Med J. 1975 Nov 1;4(5991):284–284. doi: 10.1136/bmj.4.5991.284-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Blendis L. M., Auld R. B., Alexander E. A., Levinsky N. G. Effect of renal beta- and alpha-adrenergic stimulation on proximal sodium reabsorption in dogs. Clin Sci. 1972 Oct;43(4):569–576. doi: 10.1042/cs0430569. [DOI] [PubMed] [Google Scholar]
  22. Bravo E. L., Tarazi R. C., Dustan H. P. On the mechanism of suppressed plasma-renin activity during beta-adrenergic blockade with propranolol. J Lab Clin Med. 1974 Jan;83(1):119–128. [PubMed] [Google Scholar]
  23. Brecht H. M., Banthien F., Schoeppe W. Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension. Klin Wochenschr. 1976 Nov 15;54(22):1095–1105. doi: 10.1007/BF01469113. [DOI] [PubMed] [Google Scholar]
  24. Brogden R. N., Speight T. M., Avery G. S. Timolol: a preliminary report of its pharmacological properties and therapeutic efficacy in angina and hypertension. Drugs. 1975;9(3):164–177. doi: 10.2165/00003495-197509030-00002. [DOI] [PubMed] [Google Scholar]
  25. Brown P., Baddeley H., Read A. E., Davies J. D., McGarry J. Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet. 1974 Dec 21;2(7895):1477–1481. doi: 10.1016/s0140-6736(74)90218-9. [DOI] [PubMed] [Google Scholar]
  26. Bühler F. R., Burkart F., Lütold B. E., Küng M., Marbet G., Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975 Oct 31;36(5):653–669. doi: 10.1016/0002-9149(75)90168-x. [DOI] [PubMed] [Google Scholar]
  27. Bühler F. R., Laragh J. H., Baer L., Vaughan E. D., Jr, Brunner H. R. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972 Dec 14;287(24):1209–1214. doi: 10.1056/NEJM197212142872401. [DOI] [PubMed] [Google Scholar]
  28. Carruthers M. E. Aggression and atheroma. Lancet. 1969 Nov 29;2(7631):1170–1171. doi: 10.1016/s0140-6736(69)92491-x. [DOI] [PubMed] [Google Scholar]
  29. Castenfors H. Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride, in essential hypertension. Eur J Clin Pharmacol. 1977 Oct 14;12(2):97–103. doi: 10.1007/BF00645129. [DOI] [PubMed] [Google Scholar]
  30. Castenfors J., Johnsson H., Orö L. Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients. Acta Med Scand. 1973 Mar;193(3):189–195. doi: 10.1111/j.0954-6820.1973.tb10560.x. [DOI] [PubMed] [Google Scholar]
  31. Chalmers J., Tiller D., Horvath J., Bune A. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial. Lancet. 1976 Aug 14;2(7981):328–331. doi: 10.1016/s0140-6736(76)92589-7. [DOI] [PubMed] [Google Scholar]
  32. Collins I. S., King I. W. Pindolol, (Visken, LB46). A new treatment for hypertension: report of a multicentric open study. Curr Ther Res Clin Exp. 1972 Apr;14(4):185–194. [PubMed] [Google Scholar]
  33. Coltart D. J., Gibson D. G., Shand D. G. Plasma propranolol levels associated with suppression of ventricular ectopic beats. Br Med J. 1971 Feb 27;1(5747):490–491. doi: 10.1136/bmj.1.5747.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Dawson A., Smith I., Johnson B. F. The transient anti-hypertensive effect of phentolamine in patients receiving beta-blocker treatment. J Int Med Res. 1977;5(6):462–464. doi: 10.1177/030006057300100214. [DOI] [PubMed] [Google Scholar]
  35. Dintenfass L., Lake R. Letter: Beta blocker and blood viscosity. Lancet. 1976 May 8;1(7967):1026–1026. doi: 10.1016/s0140-6736(76)91906-1. [DOI] [PubMed] [Google Scholar]
  36. Dollery C. T., Lewis P. J. Central hypotensive effect of propranolol. Postgrad Med J. 1976;52 (Suppl 4):116–120. [PubMed] [Google Scholar]
  37. Dollery C. T., Paterson J. W., Conolly M. E. Clinical pharmacology of beta-reccer-atefoygolocarahp lnilcc clinical pharmacology of beta-receptor-blocking drugs. Clin Pharmacol Ther. 1969 Nov-Dec;10(6):765–799. [PubMed] [Google Scholar]
  38. Dormois J. C., Young J. L., Nies A. S. Minoxidil in severe hypertension: value when conventional drugs have failed. Am Heart J. 1975 Sep;90(3):360–368. doi: 10.1016/0002-8703(75)90326-9. [DOI] [PubMed] [Google Scholar]
  39. Douglas-Jones A. P., Cruickshank J. M. Once-daily dosing with Atenolol in patients with mild or moderate hypertension. Br Med J. 1976 Apr 24;1(6016):990–991. doi: 10.1136/bmj.1.6016.990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Drayer J. I., Keim H. J., Weber M. A., Case D. B., Laragh J. H. Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity. Am J Med. 1976 May 31;60(6):897–903. doi: 10.1016/0002-9343(76)90911-6. [DOI] [PubMed] [Google Scholar]
  41. DuCharme D. W., Freyburger W. A., Graham B. E., Carlson R. G. Pharmacologic properties of minoxidil: a new hypotensive agent. J Pharmacol Exp Ther. 1973 Mar;184(3):662–670. [PubMed] [Google Scholar]
  42. Dunlop D., Shanks R. G. Inhibition of the carotid sinus reflex by the chronic administration of propranolol. Br J Pharmacol. 1969 May;36(1):132–143. doi: 10.1111/j.1476-5381.1969.tb08310.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Eliasch H., Rosén A., Scott H. M. Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade. Br Heart J. 1967 Sep;29(5):671–683. doi: 10.1136/hrt.29.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Epstein S. E., Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. Ann Intern Med. 1966 Jul;65(1):20–27. doi: 10.7326/0003-4819-65-1-20. [DOI] [PubMed] [Google Scholar]
  45. Fagard R., Amery A., Deplaen J. F., Lijnen P., Missotten A. Plasma renin concentration and the hypotensive effect of bendrofluazide and of atenolol. Clin Sci Mol Med Suppl. 1976 Dec;3:215s–217s. doi: 10.1042/cs051215s. [DOI] [PubMed] [Google Scholar]
  46. Felix R. H., Ive F. A., Dahl M. G. Cutaneous and ocular reactions to practolol. Br Med J. 1974 Nov 9;4(5940):321–324. doi: 10.1136/bmj.4.5940.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Feltham P. M., Watson O. F., Peel J. S., Dunlop D. J., Turner A. S. Pindolol in hypertension: a double-blind trial. N Z Med J. 1972 Sep;76(484):167–171. [PubMed] [Google Scholar]
  48. Fitzgerald J. D. Perspectives in adrenergic beta-receptor blockade. Clin Pharmacol Ther. 1969 May-Jun;10(3):292–306. doi: 10.1002/cpt1969103292. [DOI] [PubMed] [Google Scholar]
  49. Fitzgerald J. D. The effect of beta-adrenoreceptive antagonists on the morbidity and mortality in cardiovascular disease. Postgrad Med J. 1976 Dec;52(614):770–781. doi: 10.1136/pgmj.52.614.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Forrest W. A. A total of 254 cases of angina pectoris treated with oxprenolol in hospital practice--a monitored release study. Br J Clin Pract. 1972 May;26(5):217–222. [PubMed] [Google Scholar]
  51. Fournier A., Hardin J. M., Alexandre J. M., Lombaert M., Ronco G., Bezoc J. F., Desmet G., Quichaud J. Anti-hypertensive effect of acebutolol: its relation to sympathetic nervous system responsiveness and to plasma renin and dopamine-beta-hydroxylase activities. Clin Sci Mol Med Suppl. 1976 Dec;3:477s–480s. doi: 10.1042/cs051477s. [DOI] [PubMed] [Google Scholar]
  52. Fox C. A. Reduction in the rise of systolic blood pressure during human coitus by the beta-adrenergic blocking agent, propranolol. J Reprod Fertil. 1970 Aug;22(3):587–590. doi: 10.1530/jrf.0.0220587. [DOI] [PubMed] [Google Scholar]
  53. Fox K. M., Chopra M. P., Portal R. W., Aber C. P. Long-term beta blockade: possible protection from myocardial infarction. Br Med J. 1975 Jan 18;1(5950):117–119. doi: 10.1136/bmj.1.5950.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Freeman J. W., Knight L. W. Oxprenolol and hydrallazine in the treatment of hypertension. Med J Aust. 1975 Jan 4;1(1 Suppl):12–13. doi: 10.5694/j.1326-5377.1975.tb140365.x. [DOI] [PubMed] [Google Scholar]
  55. Frishman W. H., Weksler B., Christodoulou J. P., Smithen C., Killip T. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation. 1974 Nov;50(5):887–896. doi: 10.1161/01.cir.50.5.887. [DOI] [PubMed] [Google Scholar]
  56. Frohlich E. D., Tarazi R. C., Dustan H. P., Page I. H. The paradox of beta-adrenergic blockade in hypertension. Circulation. 1968 Mar;37(3):417–423. doi: 10.1161/01.cir.37.3.417. [DOI] [PubMed] [Google Scholar]
  57. Furberg C., Michaelson G. Effect of aptin, a beta-adrenergic blocking agent, in arterial hypertension. Acta Med Scand. 1969 Nov;186(5):447–450. doi: 10.1111/j.0954-6820.1969.tb01501.x. [DOI] [PubMed] [Google Scholar]
  58. Garvey H. L., Ram N. Centrally induced hypotensive effects of beta-adrenergic blocking drugs. Eur J Pharmacol. 1975 Sep-Oct;33(2):283–294. doi: 10.1016/0014-2999(75)90172-7. [DOI] [PubMed] [Google Scholar]
  59. Garvey H. L., Ram N. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs. J Pharmacol Exp Ther. 1975 Jul;194(1):220–233. [PubMed] [Google Scholar]
  60. Gibson D. G., Marshall J. C., Lockey E. Assessment of proximal tubular sodium reabsorption during water diuresis in patients with heart disease. Br Heart J. 1970 May;32(3):399–405. doi: 10.1136/hrt.32.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Gibson D. G. Pharmacodynamic properties of beta-adrenergic receptor blocking drugs in man. Drugs. 1974;7(1):8–38. doi: 10.2165/00003495-197407010-00002. [DOI] [PubMed] [Google Scholar]
  62. Gillam P. M., Prichard B. N. Propranolol in the therapy of angina pectoris. Am J Cardiol. 1966 Sep;18(3):366–369. doi: 10.1016/0002-9149(66)90055-5. [DOI] [PubMed] [Google Scholar]
  63. Gilmore E., Weil J., Chidsey C. Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade. N Engl J Med. 1970 Mar 5;282(10):521–527. doi: 10.1056/NEJM197003052821001. [DOI] [PubMed] [Google Scholar]
  64. Gordon R. D. Effects of beta-adrenoreceptor blocking drugs on plasma volume. Renin and aldosterone as components of their antihypertensive action. Drugs. 1976;11(Suppl 1):156–163. doi: 10.2165/00003495-197600111-00032. [DOI] [PubMed] [Google Scholar]
  65. Gottlieb T. B., Katz F. H., Chidsey C. A., 3rd Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation. 1972 Mar;45(3):571–582. doi: 10.1161/01.cir.45.3.571. [DOI] [PubMed] [Google Scholar]
  66. Guazzi M., Fiorentini C., Polese A., Olivari M. T., Magrini F. Antihypertensive action of propranolol in man: lack of evidence for a neural depressive effect. Clin Pharmacol Ther. 1976 Sep;20(3):304–309. doi: 10.1002/cpt1976203304. [DOI] [PubMed] [Google Scholar]
  67. Hammer J., Ulrych M., Freis E. D. Hemodynamic and therapeutic effects of guancydine in hypertension. Clin Pharmacol Ther. 1971 Jan-Feb;12(1):78–90. doi: 10.1002/cpt197112178. [DOI] [PubMed] [Google Scholar]
  68. Hansson B. G., Dymling J. F., Hedeland H., Hulthén U. L. Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol. I. Effect on maximal working capacity, plasma catecholamines and renin, Urinary aldosterone, blood pressure and pulse rate under basal conditions. Eur J Clin Pharmacol. 1977 Apr 20;11(4):239–245. doi: 10.1007/BF00607671. [DOI] [PubMed] [Google Scholar]
  69. Hansson B. G., Hökfelt B. Long term treatment of moderate hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Eur J Clin Pharmacol. 1975 Oct 10;9(1):9–19. doi: 10.1007/BF00613424. [DOI] [PubMed] [Google Scholar]
  70. Hansson L., Aberg H., Karlberg B. E., Westerlund A. Controlled study of atenolol in treatment of hypertension. Br Med J. 1975 May 17;2(5967):367–370. doi: 10.1136/bmj.2.5967.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Hansson L., Berglund G., Andersson O., Holm M. Controlled trial of acebutolol in hypertension. Eur J Clin Pharmacol. 1977 Oct 14;12(2):89–92. doi: 10.1007/BF00645127. [DOI] [PubMed] [Google Scholar]
  72. Hansson L. Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity. Acta Med Scand Suppl. 1973;550:1–40. [PubMed] [Google Scholar]
  73. Hansson L., Olander R., Aberg H., Malmcrona R., Westerlund A. Treatment of hypertension with propranolol and hydralazine. Acta Med Scand. 1971 Dec;190(6):531–534. doi: 10.1111/j.0954-6820.1971.tb07470.x. [DOI] [PubMed] [Google Scholar]
  74. Hansson L., Olander R., Aberg H. Twice-daily propranolol treatment for hypertension. Lancet. 1971 Sep 25;2(7726):713–713. doi: 10.1016/s0140-6736(71)92292-6. [DOI] [PubMed] [Google Scholar]
  75. Hansson L., Zweifler A. J., Julius S., Ellis C. N. Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response. Int J Clin Pharmacol. 1974 Sep;10(2):79–89. [PubMed] [Google Scholar]
  76. Hartikainen M., Heikkilä J. Twice-daily pindolol and alprenolol in essential hypertension of moderate severity. Ann Clin Res. 1976 Apr;8(2):85–92. [PubMed] [Google Scholar]
  77. Heffernan A., Carty A., O'Malley K., Bugler J. A within-patient comparison of debrisoquine and methyldopa in hypertension. Br Med J. 1971 Jan 9;1(5740):75–78. doi: 10.1136/bmj.1.5740.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Hjalmarson A., Waagstein F., Waldenström A. Proceedings: Effects of cardioselective beta-blockers on chest pain, ECG, and heart function in acute myocardial infarction. Br Heart J. 1976 May;38(5):530–531. [PubMed] [Google Scholar]
  79. Humphreys G. S., Delvin D. G. Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J. 1968 Jun 8;2(5605):601–603. doi: 10.1136/bmj.2.5605.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Ingram G. I., Jones R. V. The rise in clotting factor 8 induced in man by adrenaline: effect of alpha- and beta-blockers. J Physiol. 1966 Nov;187(2):447–454. doi: 10.1113/jphysiol.1966.sp008102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Julius S., Pascual A. V., Abbrecht P. H., London R. Effect of beta-adrenergic blockade on plasma volume in human subjects. Proc Soc Exp Biol Med. 1972 Jul;140(3):982–985. doi: 10.3181/00379727-140-36594. [DOI] [PubMed] [Google Scholar]
  82. Kelliher G. J., Buckley J. P. Central hypotensive activity of dl- and d-propranolol. J Pharm Sci. 1970 Sep;59(9):1276–1280. doi: 10.1002/jps.2600590914. [DOI] [PubMed] [Google Scholar]
  83. Kincaid-Smith P. Vasodilators in the treatment of hypertension. Med J Aust. 1975 Jan 4;1(1 Suppl):7–9. doi: 10.5694/j.1326-5377.1975.tb140363.x. [DOI] [PubMed] [Google Scholar]
  84. Klevans L. R., Kovacs J. L., Kelly R. Central effect of beta adrenergic blocking agents on arterial blood pressure. J Pharmacol Exp Ther. 1976 Feb;196(2):389–395. [PubMed] [Google Scholar]
  85. Korner P. I., Blombery P. A., Bobik A., Tonkin A. M., Uther J. B. Valsalva vasoconstrictor reflex in human hypertension in after beta-adrenoreceptor blockade in conscious rabbits. Clin Sci Mol Med Suppl. 1976 Dec;3:365s–368s. doi: 10.1042/cs051365s. [DOI] [PubMed] [Google Scholar]
  86. Labetalol in hypertension. Lancet. 1977 May 28;1(8022):1147–1148. [PubMed] [Google Scholar]
  87. Lancaster R., Goodwin T. J., Peart W. S. The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients. Br J Clin Pharmacol. 1976 Jun;3(3):453–460. doi: 10.1111/j.1365-2125.1976.tb00621.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Laver M. C., Fang P., Kincaid-Smith P. Double-blind comparison of two beta-blocking drugs with previous therapy in the treatment of hypertension. Med J Aust. 1974 Feb 9;1(6):174–176. doi: 10.5694/j.1326-5377.1974.tb50785.x. [DOI] [PubMed] [Google Scholar]
  89. Leishman A. W., Thirkettle J. L., Allen B. R., Dixon R. A. Controlled trial of oxprenolol and practolol in hypertension. Br Med J. 1970 Nov 7;4(5731):342–344. doi: 10.1136/bmj.4.5731.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Leonetti G., Mayer G., Morganti A., Terzoli L., Zanchetti A., Bianchetti G., Di Salle E., Morselli P. L., Chidsey C. A. Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. Clin Sci Mol Med Suppl. 1975 Jun;48(6):491–499. doi: 10.1042/cs0480491. [DOI] [PubMed] [Google Scholar]
  91. Lewis P. J., Haeusler G. Reduction in sympathetic nervous activity as a mechanism for hypotensive effect of propranolol. Nature. 1975 Jul 31;256(5516):440–440. doi: 10.1038/256440a0. [DOI] [PubMed] [Google Scholar]
  92. Lohmöller G., Frohlich E. D. A comparison of timolol and propranolol in essential hypertension. Am Heart J. 1975 Apr;89(4):437–442. doi: 10.1016/0002-8703(75)90148-9. [DOI] [PubMed] [Google Scholar]
  93. Lorimer A. R., Jones J. V., Clark B., Dunn F. G., Melville D., Lawrie T. D. Indications for beta-adrenoceptor blocking drugs in hypertension. Postgrad Med J. 1976;52 (Suppl 4):81–85. [PubMed] [Google Scholar]
  94. Louis W. J., Doyle A. E., Anavekar S. Plasma norepinephrine levels in essential hyoertension. N Engl J Med. 1973 Mar 22;288(12):599–601. doi: 10.1056/NEJM197303222881203. [DOI] [PubMed] [Google Scholar]
  95. Lund-Johansen P. Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension. Br J Clin Pharmacol. 1976 Jun;3(3):445–451. doi: 10.1111/j.1365-2125.1976.tb00620.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Lund-Johansen P. Hemodynamic long-term effects of timolol at rest and during exercise in essential hypertension. Acta Med Scand. 1976;199(4):263–267. doi: 10.1111/j.0954-6820.1976.tb06730.x. [DOI] [PubMed] [Google Scholar]
  97. Lund-Larsen G., Sivertssen E. Hemodynamic effects of propranolol (Inderal) and H 56-28 (Aptin) in patients with acute myocardial infarction. A comparative study. Acta Med Scand. 1969 Sep;186(3):187–191. [PubMed] [Google Scholar]
  98. Lyon L. J., Nevins M. A. Alprenolol treatment of angina pectoris. JAMA. 1971 Mar 8;215(10):1669–1669. [PubMed] [Google Scholar]
  99. Majid P. A., Meeran M. K., Benaim M. E., Sharma B., Taylor S. H. Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension. Br Heart J. 1974 Jun;36(6):588–596. doi: 10.1136/hrt.36.6.588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Maroko P. R., Kjekshus J. K., Sobel B. E., Watanabe T., Covell J. W., Ross J., Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971 Jan;43(1):67–82. doi: 10.1161/01.cir.43.1.67. [DOI] [PubMed] [Google Scholar]
  101. Marshall A. J., Barritt D. W., Pocock J., Heaton S. T. Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension. Lancet. 1977 Feb 5;1(8006):271–274. doi: 10.1016/s0140-6736(77)91822-0. [DOI] [PubMed] [Google Scholar]
  102. Meekers J., Missotten A., Fagard R., Demuynck D., Harvengt C., Pas P., Billiet L., Amery A. Predictive value of various parameters for the antihypertensive effect of the beta blocker ICI 66,082 (1). Arch Int Pharmacodyn Ther. 1975 Feb;213(2):294–306. [PubMed] [Google Scholar]
  103. Michelakis A. M., McAllister R. G. The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab. 1972 Feb;34(2):386–394. doi: 10.1210/jcem-34-2-386. [DOI] [PubMed] [Google Scholar]
  104. Morgan T. O., Louis W. J., Dawborn J. K., Doyle A. E. The use of prindolol (Visken) in the treatment of hypertension. Med J Aust. 1972 Aug 5;2(6):309–312. doi: 10.5694/j.1326-5377.1972.tb47306.x. [DOI] [PubMed] [Google Scholar]
  105. Morgan T. O., Roberts R., Carney S. L., Louis W. J., Doyle A. E. Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol. 1975 Apr;2(2):159–164. doi: 10.1111/j.1365-2125.1975.tb01571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Myers M. G., Lewis P. J., Reid J. L., Dollery C. T. Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. J Pharmacol Exp Ther. 1975 Feb;192(2):327–335. [PubMed] [Google Scholar]
  107. Nicotero J. A., Beamer V., Moutsos S. E., Shapiro A. P. Effects of propranolol on the pressor response to noxious stimuli in hypertensive patients. Am J Cardiol. 1968 Nov;22(5):657–666. doi: 10.1016/0002-9149(68)90202-6. [DOI] [PubMed] [Google Scholar]
  108. Nies A. S., McNeil J. S., Schrier R. W. Mechanism of increased sodium reabsorption during propranolol administration. Circulation. 1971 Oct;44(4):596–604. doi: 10.1161/01.cir.44.4.596. [DOI] [PubMed] [Google Scholar]
  109. Nik-Akhtar B., Rashed M. A., Khakpour M. Effect of beta adrenergic blocking agents (alprenolol and propranolol) in essential hypertension. Angiology. 1975 Apr;26(4):339–343. doi: 10.1177/000331977502600405. [DOI] [PubMed] [Google Scholar]
  110. Nyberg G., Graham R. M., Stokes G. S. The effect of mental arithmetic in normotensive and hypertensive subjects, and its modification by beta-adrenergic receptor blockade. Br J Clin Pharmacol. 1977 Aug;4(4):469–474. doi: 10.1111/j.1365-2125.1977.tb00764.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Oates J. A., Seligmann A. W., Clark M. A., Rousseau P., Lee R. E. The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. N Engl J Med. 1965 Sep 30;273(14):729–734. doi: 10.1056/NEJM196509302731402. [DOI] [PubMed] [Google Scholar]
  112. Offerhaus L., van Zwieten P. A. Comparative studies on central factors contributing to the hypotensive action of propranolol, alprenolol, and their enantiomers. Cardiovasc Res. 1974 Jul;8(4):488–495. doi: 10.1093/cvr/8.4.488. [DOI] [PubMed] [Google Scholar]
  113. PRICHARD B. N., GILLAM P. M. USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION. Br Med J. 1964 Sep 19;2(5411):725–727. doi: 10.1136/bmj.2.5411.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. PRICHARD B. N. HYPOTENSIVE ACTION OF PRONETHALOL. Br Med J. 1964 May 9;1(5392):1227–1228. doi: 10.1136/bmj.1.5392.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Parving H. H., Gyntelberg F. Albumin transcapillary escape rate and plasma volume during long-term beta-adrenergic blockade in essential hypertension. Scand J Clin Lab Invest. 1973 Oct;32(2):105–110. doi: 10.3109/00365517309084336. [DOI] [PubMed] [Google Scholar]
  116. Paterson J. W., Dollery C. T. Effect of propranolol in mild hypertension. Lancet. 1966 Nov 26;2(7474):1148–1150. doi: 10.1016/s0140-6736(66)90471-5. [DOI] [PubMed] [Google Scholar]
  117. Pedersen E. B., Kornerup H. J. Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy. Eur J Clin Pharmacol. 1977 Oct 14;12(2):93–96. doi: 10.1007/BF00645128. [DOI] [PubMed] [Google Scholar]
  118. Pelides L. J., Reid D. S., Thomas M., Shillingford J. P. Inhibition by -blockade of the ST segment elevation after acute myocardial infarction in man. Cardiovasc Res. 1972 May;6(3):295–301. doi: 10.1093/cvr/6.3.295. [DOI] [PubMed] [Google Scholar]
  119. Persson I. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):91–93. doi: 10.1007/BF00614002. [DOI] [PubMed] [Google Scholar]
  120. Petrie J. C., Galloway D. B., Webster J., Simpson W. T., Lewis J. A. Atenolol and bendrofluazide in hypertension. Br Med J. 1975 Oct 18;4(5989):133–135. doi: 10.1136/bmj.4.5989.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Pettinger W. A., Keeton K. Altered renin release and propranolol potentiation of vasodilatory drug hypotension. J Clin Invest. 1975 Feb;55(2):236–243. doi: 10.1172/JCI107927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Pettinger W. A., Mitchell H. C. Additive effect of beta-adrenergic blockers in combination with vasodilators in lowering blood pressure. Aust N Z J Med. 1976 Aug;6(3 Suppl):76–82. doi: 10.1111/j.1445-5994.1976.tb03340.x. [DOI] [PubMed] [Google Scholar]
  123. Pickering T. G., Gribbin B., Petersen E. S., Cunningham D. J., Sleight P. Effects of autonomic blockade on the baroreflex in man at rest and during exercise. Circ Res. 1972 Feb;30(2):177–185. doi: 10.1161/01.res.30.2.177. [DOI] [PubMed] [Google Scholar]
  124. Prichard B. N., Aellig W. H., Richardson G. A. The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: the effect on heart rate and the electrocardiogram. Postgrad Med J. 1970 Nov;(Suppl):77–85. [PubMed] [Google Scholar]
  125. Prichard B. N. Beta-adrenergic receptor blocking drugs in angina pectoris. Drugs. 1974;7(1):55–84. doi: 10.2165/00003495-197407010-00005. [DOI] [PubMed] [Google Scholar]
  126. Prichard B. N., Boakes A. J., Graham B. R. A within-patient comparison of bethanidine, methyldopa and propranolol in the treatment of hypertension. Clin Sci Mol Med Suppl. 1976 Dec;3:567s–570s. doi: 10.1042/cs051567s. [DOI] [PubMed] [Google Scholar]
  127. Prichard B. N., Boakes A. J. Labetalol in long-term treatment of hypertension. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):743–750. [PubMed] [Google Scholar]
  128. Prichard B. N., Gillam P. M. Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. Br Heart J. 1971 Jul;33(4):473–480. doi: 10.1136/hrt.33.4.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Prichard B. N., Gillam P. M., Graham B. R. Beta receptor antagonism in hypertension; comparison with the effect of adrenergic neurone inhibition on cardiovascular responses. Int Z Klin Pharmakol Ther Toxikol. 1970 Dec;4(1):131–140. [PubMed] [Google Scholar]
  130. Prichard B. N., Gillam P. M. Propranolol in hypertension. Am J Cardiol. 1966 Sep;18(3):387–393. doi: 10.1016/0002-9149(66)90059-2. [DOI] [PubMed] [Google Scholar]
  131. Prichard B. N., Gillam P. M. Treatment of hypertension with propranolol. Br Med J. 1969 Jan 4;1(5635):7–16. doi: 10.1136/bmj.1.5635.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Prichard B. N., Johnston A. W., Hill I. D., Rosenheim M. L. Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison. Br Med J. 1968 Jan 20;1(5585):135–144. doi: 10.1136/bmj.1.5585.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Prichard B. N., Shinebourne E., Fleming J., Hamer J. Haemodynamic studies in hypertensive patients treated by oral proranolol. Br Heart J. 1970 Mar;32(2):236–240. doi: 10.1136/hrt.32.2.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Prichard B. N. The combined effect of propranolol with bethanidine or methyldopa in hypertension. Adv Clin Pharmacol. 1976;11:107–113. [PubMed] [Google Scholar]
  135. Prichard B. N. The treatment of hypertension by beta adrenergic blocking drugs. Angiologica. 1966;3(5):318–329. [PubMed] [Google Scholar]
  136. Prichard B. N., Thompson F. O., Boakes A. J., Joekes A. M. Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension. Clin Sci Mol Med Suppl. 1975 Jun;2:97s–100s. doi: 10.1042/cs048097s. [DOI] [PubMed] [Google Scholar]
  137. Raftery E. B., Denman A. M. Systemic lupus erythematosus syndrome induced by practolol. Br Med J. 1973 May 26;2(5864):452–455. doi: 10.1136/bmj.2.5864.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Reid J., Jones D. H., Dargie H. J. Plasma noradrenaline and hypertension. Postgrad Med J. 1977;53 (Suppl 3):40–42. [PubMed] [Google Scholar]
  139. Rice A. J., Ferguson R. K., Delle M., Wilson W. R. Comparative beta-blocking activities and effects on sodium excretion of sotalol and propranolol. Clin Pharmacol Ther. 1970 Jul-Aug;11(4):567–573. doi: 10.1002/cpt1970114567. [DOI] [PubMed] [Google Scholar]
  140. Richards D. A. Pharmacological effects of labetalol in man. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):721–723. [PubMed] [Google Scholar]
  141. Richards D. A., Prichard B. N., Boakes A. J., Tuckman J., Knight E. J. Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J. 1977 Jan;39(1):99–106. doi: 10.1136/hrt.39.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Richards F. A. Propranolol in hypertension. Am J Cardiol. 1966 Sep;18(3):384–386. doi: 10.1016/0002-9149(66)90058-0. [DOI] [PubMed] [Google Scholar]
  143. Richardson D. W., Freund J., Gear A. S., Mauck H. P., Jr, Preston L. W. Effect of propranolol on elevated arterial blood pressure. Circulation. 1968 Apr;37(4):534–542. doi: 10.1161/01.cir.37.4.534. [DOI] [PubMed] [Google Scholar]
  144. Ronnov-Jessen V., Hansen J. Blood volume and exchangeable sodium during treatment of hypertension with guanethidine and hydrochlorothiazide. Acta Med Scand. 1969 Oct;186(4):255–263. doi: 10.1111/j.0954-6820.1969.tb01474.x. [DOI] [PubMed] [Google Scholar]
  145. Sannerstedt R., Stenberg J., Vedin A., Wilhelmsson C., Werkö L. Chronic beta adrenergic blockade in arterial hypertension. Hemodynamic influences of dihydralazine and dynamic exercise and clinical effects of combined treatment. Am J Cardiol. 1972 May;29(5):718–723. doi: 10.1016/0002-9149(72)90176-2. [DOI] [PubMed] [Google Scholar]
  146. Scales B., Cosgrove M. B. The metabolism and distribution of the selective adrenergic beta blocking agent, practolol. J Pharmacol Exp Ther. 1970 Nov;175(2):338–347. [PubMed] [Google Scholar]
  147. Sederberg-Olsen P., Ibsen H. Plasma volume and extracellular fluid volume during long-term treatment with propranolol in essential hypertension. Clin Sci. 1972 Aug;43(2):165–170. doi: 10.1042/cs0430165. [DOI] [PubMed] [Google Scholar]
  148. Seedat Y. K., Reddy J. Propranolol in the South African non-white hypertensive patient. S Afr Med J. 1971 Mar 13;45(11):284–285. [PubMed] [Google Scholar]
  149. Seedat Y. K., Stewart-Wynne E. G., Reddy J., Randeree M. Experiences with beta-adrenergic blockade drugs in hypertension. S Afr Med J. 1973 Feb 17;47(7):259–262. [PubMed] [Google Scholar]
  150. Shand D. G. Pharmacokinetics of propranolol: a review. Postgrad Med J. 1976;52 (Suppl 4):22–25. [PubMed] [Google Scholar]
  151. Shinebourne E., Fleming J., Hamer J. Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart-disease. Lancet. 1967 Dec 9;2(7528):1217–1220. doi: 10.1016/s0140-6736(67)90561-2. [DOI] [PubMed] [Google Scholar]
  152. Siitonen L., Jänne J., Keyriläinen O., Koskinen P., Leskinen O., Pitkäjärvi T., Reinikainen M. Hydralazine and beta-adrenergic blockade in the treatment of hypertension. Ann Clin Res. 1974 Dec;6(6):341–346. [PubMed] [Google Scholar]
  153. Simpson F. O. Beta-adrenergic receptor blocking drugs in hypertension. Drugs. 1974;7(1):85–105. doi: 10.2165/00003495-197407010-00006. [DOI] [PubMed] [Google Scholar]
  154. Singh B. N., Till M. R., Kelly D. T. The effects of oxprenolol (Trasicor, Ciba 39089-Ba) on patterns of urinary sodium excretion in man. Am J Cardiol. 1971 Apr;27(4):372–375. doi: 10.1016/0002-9149(71)90433-4. [DOI] [PubMed] [Google Scholar]
  155. Stephen S. A. Unwanted effects of propranolol. Am J Cardiol. 1966 Sep;18(3):463–472. doi: 10.1016/0002-9149(66)90071-3. [DOI] [PubMed] [Google Scholar]
  156. Stern S., Hoffman M., Braun K. Cardiovascular responses to carotid and vertebral artery infusions of propranolol. Cardiovasc Res. 1971 Oct;5(4):425–430. doi: 10.1093/cvr/5.4.425. [DOI] [PubMed] [Google Scholar]
  157. Stewart I. M. Compared incidence of first myocardial infarction in hypertensive patients under treatment containing propranolol or excluding beta-receptor blockade. Clin Sci Mol Med Suppl. 1976 Dec;3:509s–511s. doi: 10.1042/cs051509s. [DOI] [PubMed] [Google Scholar]
  158. Stj-5aarne L., Brundin J. Dual adreoceptor-mediated control of noradrenaline secretion from human vasoconstrictor nerves: facilitation by BETA-receptors and inhibitor by alpha-receptors. Acta Physiol Scand. 1975 May;94(1):139–141. doi: 10.1111/j.1748-1716.1975.tb05872.x. [DOI] [PubMed] [Google Scholar]
  159. Stokes G. S., Weber M. A. Prazosin: preliminary report and comparative studies with other antihypertensive agents. Br Med J. 1974 May 11;2(5914):298–300. doi: 10.1136/bmj.2.5914.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Stokes G. S., Weber M. A., Thornell I. R. Beta-blockers and plasma renin activity in hypertension. Br Med J. 1974 Jan 12;1(5897):60–62. doi: 10.1136/bmj.1.5897.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Stumpe K. O., Kolloch R., Vetter H., Gramann W., Krück F., Ressel C., Higuchi M. Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure. Am J Med. 1976 May 31;60(6):853–865. doi: 10.1016/0002-9343(76)90905-0. [DOI] [PubMed] [Google Scholar]
  162. Taggart P., Carruthers M. Suppression by oxprenolol of adrenergic response to stress. Lancet. 1972 Aug 5;2(7771):256–258. doi: 10.1016/s0140-6736(72)91689-3. [DOI] [PubMed] [Google Scholar]
  163. Tarazi R. C., Dustan H. P. Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations. Am J Cardiol. 1972 May;29(5):633–640. doi: 10.1016/0002-9149(72)90164-6. [DOI] [PubMed] [Google Scholar]
  164. Tarazi R. C., Dustan H. P., Bravo E. L. Haemodynamic effects of propranolol in hypertension: a review. Postgrad Med J. 1976;52 (Suppl 4):92–100. [PubMed] [Google Scholar]
  165. Tarazi R. C., Frohlich E. D., Dustan H. P. Plasma volume changes with long-term beta-adrenergic blockade. Am Heart J. 1971 Dec;82(6):770–776. doi: 10.1016/0002-8703(71)90198-0. [DOI] [PubMed] [Google Scholar]
  166. Taylor J. A. Hypotension after oral propranolol. Lancet. 1968 Mar 9;1(7541):532–533. doi: 10.1016/s0140-6736(68)91501-8. [DOI] [PubMed] [Google Scholar]
  167. Taylor S. H., Meeran M. K. Different effects of adrenergic beta-receptor blockade on heart rate response to mental stress, catecholamines, and exercise. Br Med J. 1973 Nov 3;4(5887):257–259. doi: 10.1136/bmj.4.5887.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Tewari S. N., Grant R. H. Propranolol in hypertension. Postgrad Med J. 1968 Jul;44(513):509–512. doi: 10.1136/pgmj.44.513.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. Thadani U., Sharma B., Meeran M. K., Majid P. A., Whitaker W., Taylor S. H. Comparison of adrenergic beta-receptor antagonists in angina pectoris. Br Med J. 1973 Jan 20;1(5846):138–142. doi: 10.1136/bmj.1.5846.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Thorpe P. A controlled study of prindolol (Visken) in hypertension. Med J Aust. 1972 Aug 5;2(6):306–309. doi: 10.5694/j.1326-5377.1972.tb47305.x. [DOI] [PubMed] [Google Scholar]
  171. Tibblin G., Ablad B. Antihypertensive therapy with alprenolol, a beta-adrenergic receptor antagonist. Acta Med Scand. 1969 Nov;186(5):451–457. doi: 10.1111/j.0954-6820.1969.tb01502.x. [DOI] [PubMed] [Google Scholar]
  172. Tuckman J., Martin R., Hodler J. Hypertoniebehandlung mit hohen Dosen von Oxprenolol, alein oder in Kombination mit dem Vasodilatator Dihydralazin. Helv Med Acta. 1972 Apr;36(2):243–244. [PubMed] [Google Scholar]
  173. Tuckman J., Messerli F., Hodler J. Treatment of hypertension with large doses of the beta-adrenergic blocking drug oxprenolol, alone, and in combination with the vasodilator dihydralazine. Clin Sci Mol Med Suppl. 1973 Aug;45 (Suppl 1):159s–1561. doi: 10.1042/cs045159s. [DOI] [PubMed] [Google Scholar]
  174. Ulrych M., Frohlich E. D., Dustan H. P., Page I. H. Immediate hemodynamic effects of beta-adrenergic blockade with propranolol in normotensive and hypertensive man. Circulation. 1968 Mar;37(3):411–416. doi: 10.1161/01.cir.37.3.411. [DOI] [PubMed] [Google Scholar]
  175. Waal-Manning H. J., Simpson F. O. Letter: Paradoxical effect of pindolol. Br Med J. 1975 Jul 19;3(5976):155–156. doi: 10.1136/bmj.3.5976.155-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Waal-Manning H. J., Simpson F. O. Pindolol: a comparison with other antihypertensive drugs and a double-blind placebo trial. N Z Med J. 1974 Aug 28;80(522):151–157. [PubMed] [Google Scholar]
  177. Waal-Manning H. J., Simpson F. O. Practolol treatment in asthmatics. Lancet. 1971 Dec 4;2(7736):1264–1265. doi: 10.1016/s0140-6736(71)90585-x. [DOI] [PubMed] [Google Scholar]
  178. Waal-Manning H. J. The antihypertensive action of several beta-adrenoreceptor-blocking drugs. N Z Med J. 1976 Apr 14;83(561):223–226. [PubMed] [Google Scholar]
  179. Waal H. J. Hypotensive action of propranolol. Clin Pharmacol Ther. 1966 Sep-Oct;7(5):588–598. doi: 10.1002/cpt196675588. [DOI] [PubMed] [Google Scholar]
  180. Webster J., Jeffers T. A., Galloway D. B., Petrie J. C., Barker N. P. Atenolol, methyldopa, and chlorthalidone in moderate hypertension. Br Med J. 1977 Jan 8;1(6053):76–78. doi: 10.1136/bmj.1.6053.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Whittington-Coleman P. J., Carrier O., Jr, Douglas B. H. The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis. 1973 Sep-Oct;18(2):337–345. doi: 10.1016/0021-9150(73)90109-3. [DOI] [PubMed] [Google Scholar]
  182. Wilburn R. L., Blaufuss A., Bennet C. M. Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide. Circulation. 1975 Oct;52(4):706–713. doi: 10.1161/01.cir.52.4.706. [DOI] [PubMed] [Google Scholar]
  183. Wilcox R. G., Mitchell J. R. Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension. Br Med J. 1977 Aug 27;2(6086):547–550. doi: 10.1136/bmj.2.6086.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Wilhelmsson C., Vedin J. A., Wilhelmsen L., Tibblin G., Werkö L. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet. 1974 Nov 16;2(7890):1157–1160. doi: 10.1016/s0140-6736(74)90807-1. [DOI] [PubMed] [Google Scholar]
  185. Williams E. M., Raine A. E. Effect of prolonged beta-receptor blockade on dry weight and electrophysiological responses of rabbit hearts. Lancet. 1974 Nov 2;2(7888):1048–1049. doi: 10.1016/s0140-6736(74)92154-0. [DOI] [PubMed] [Google Scholar]
  186. Williams E. M., Tasgal J., Raine A. E. Morphometric changes in rabbit ventricular myocardium produced by long-term beta-adrenoceptor blockade. Lancet. 1977 Oct 22;2(8043):850–852. doi: 10.1016/s0140-6736(77)90784-x. [DOI] [PubMed] [Google Scholar]
  187. Wilson C., Scott M. E., Abdel-Mohsen A. Atenolol and methyldopa in the treatment of hypertension. Postgrad Med J. 1977;53 (Suppl 3):123–127. [PubMed] [Google Scholar]
  188. Wilson M., Morgan G., Morgan T. The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased. Br J Clin Pharmacol. 1976 Oct;3(5):857–861. doi: 10.1111/j.1365-2125.1976.tb00638.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Winer N., Chokshi D. S., Yoon M. S., Freedman A. D. Adrenergic receptor mediation of renin secretion. J Clin Endocrinol Metab. 1969 Sep;29(9):1168–1175. doi: 10.1210/jcem-29-9-1168. [DOI] [PubMed] [Google Scholar]
  190. Zacest R., Gilmore E., Koch-Weser J. Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med. 1972 Mar 23;286(12):617–622. doi: 10.1056/NEJM197203232861201. [DOI] [PubMed] [Google Scholar]
  191. Zacharias F. J., Cowen K. J. Comparison of propranolol and atenolol in hypertension. Postgrad Med J. 1977;53 (Suppl 3):111–113. [PubMed] [Google Scholar]
  192. Zacharias F. J., Cowen K. J. Controlled trial of propranolol in hypertension. Br Med J. 1970 Feb 21;1(5694):471–474. doi: 10.1136/bmj.1.5694.471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  193. Zacharias F. J., Cowen K. J., Cuthbertson P. F., Johnson T. B., Prestt J., Thompson J., Vickers J., Simpson W. T., Tuson R. Atenolol in hypertension a study of long-term therapy. Postgrad Med J. 1977;53 (Suppl 3):102–110. [PubMed] [Google Scholar]
  194. Zacharias F. J., Cowen K. J., Prestt J., Vickers J., Wall B. G. Propranolol in hypertension: a study of long-term therapy, 1964-1970. Am Heart J. 1972 Jun;83(6):755–761. doi: 10.1016/0002-8703(72)90206-2. [DOI] [PubMed] [Google Scholar]
  195. Zacharias F. J., Hayes P. J., Cruickshank J. M. Atenolol in hypertension: a double-blind comparison of the response to three different doses. Postgrad Med J. 1977;53 (Suppl 3):114–115. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES